NasdaqGS:REGNBiotechs
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Dupixent’s New FDA Approval For Allergic Fungal Rhinosinusitis
The latest catalyst for Regeneron Pharmaceuticals (REGN) is US FDA approval of Dupixent for allergic fungal rhinosinusitis in patients 6 and older with prior sino nasal surgery. This expands the labeled uses of this key drug.
See our latest analysis for Regeneron Pharmaceuticals.
Despite the positive Dupixent news and other recent pipeline updates, such as the priority review for garetosmab and gene editing progress with Tessera, Regeneron Pharmaceuticals' recent share price momentum has been...